1. Home
  2. PTY vs TRVI Comparison

PTY vs TRVI Comparison

Compare PTY & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco Corporate & Income Opportunity Fund

PTY

Pimco Corporate & Income Opportunity Fund

HOLD

Current Price

$10.80

Market Cap

2.4B

Sector

Finance

ML Signal

HOLD

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

HOLD

Current Price

$13.67

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTY
TRVI
Founded
N/A
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.6B
IPO Year
2002
2019

Fundamental Metrics

Financial Performance
Metric
PTY
TRVI
Price
$10.80
$13.67
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
★ $28.18
AVG Volume (30 Days)
★ 2.0M
1.6M
Earning Date
01-01-0001
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.91
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.65
$9.29
52 Week High
$14.69
$20.22

Technical Indicators

Market Signals
Indicator
PTY
TRVI
Relative Strength Index (RSI) 33.20 24.83
Support Level N/A $13.08
Resistance Level $11.92 $14.75
Average True Range (ATR) 0.21 0.57
MACD -0.02 -0.05
Stochastic Oscillator 18.18 6.54

Price Performance

Historical Comparison
PTY
TRVI

About PTY Pimco Corporate & Income Opportunity Fund

PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on both public or private basis.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: